May 2004
Volume 45, Issue 13
ARVO Annual Meeting Abstract  |   May 2004
Vitrase® (Ovine Hyaluronidase), an investigational drug, for the treatment of vitreous hemorrhage: safety evaluation from two large Phase III studies
Author Affiliations & Notes
  • R.M. Lieberman
    Ophthalmology, Mt Sinai Medical Ctr, New York, NY
  • J.W. Chandler
    ISTA Pharmaceuticals, Inc., Irvine, CA
  • B.D. Kuppermann
    Department of Ophthalmology, University of CA, Irvine, Irvine, CA
  • E.L. Thomas
    Retina–Vitreous Associates Medical Group, Beverly Hills, CA
  • L.R. Grillone
    ISTA Pharmaceuticals, Irvine, CA
  • Footnotes
    Commercial Relationships  R.M. Lieberman, Mt Sinai Medical Ctr F, R; J.W. Chandler, ISTA Pharmaceuticals, Inc. E; B.D. Kuppermann, University of CA, Irvine F, C, R; E.L. Thomas, Retina–Vitreous Associates Medical Group F, C, R; L.R. Grillone, ISTA Pharmaceuticals, Inc. E.
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science May 2004, Vol.45, 4116. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      R.M. Lieberman, J.W. Chandler, B.D. Kuppermann, E.L. Thomas, L.R. Grillone; Vitrase® (Ovine Hyaluronidase), an investigational drug, for the treatment of vitreous hemorrhage: safety evaluation from two large Phase III studies . Invest. Ophthalmol. Vis. Sci. 2004;45(13):4116.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Abstract: : Purpose: Safety evaluation of Vitrase vs 0.9% saline. Methods: Patients with vitreous hemorrhage, >1 month; severe at entry & BCVA < 20/200; randomly assigned and received a single intravitreous injection (50 µL): saline (378), 7.5 (198), 55 (377) or 75 IU (391) Vitrase. Results: 742 patients were followed for >6 months and 535 were followed >1 year. Demographics and baseline characteristics among treatment groups were similar with a higher Hispanic representation in 7.5 IU. Between 72–88% of patients in saline and Vitrase groups had diabetes. Absolute difference in incidence of important ocular adverse events for 55 & 75 IU groups combined vs saline was highest for iritis (27%) and eye pain (17%). Difference for all other AEs was <10%, including hypopyon and retinal detachment. AEs statistically significant for all Vitrase groups included abnormal sensation in the eye, eye pain, iritis, increased lacrimation, hyperemia, photobia and photopsia. No AEs lead to study discontinuation. Most resolved by 30 days. Incidence of hypopyon was 3.5% (55 &75 IU); mean duration was 8 and 10 days, respectively. All hypopyon were considered sterile and related to test agent. The majority required medication. No hypopyon was reported for saline group. Iritis was of short duration: mean duration was 40 (saline), 31 (55 IU) and 27 (75 IU) days. Iritis requiring treatment: 41% (saline), 50% (55 IU) and 47% (75 IU). Mean duration of iritis requiring treatment was similar in all episodes and groups, whether treated or not. The majority of retinal detachments were judged unrelated to test agent. Incidence of recurrent hemorrhage and visual acuity reduction were statistically significant vs saline, but without a dose response. There were no cases of endophthalmitis. Conclusions: Safety of Vitrase is comparable to saline with the exception of iritis, hypopyon. Hypopyon were sterile, easily managed, and transient; iritis was easily managed and resolved quickly. Vitrase (55/75 IU) is safe for intravitreous injection.

Keywords: clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • diabetic retinopathy • vitreous 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.